Some of the world's most powerful tech leaders have set aside their mutual rivalries. In a joint open letter, they are urging U.S. lawmakers to pass new legislation that would make it harder to use artificial intelligence in the development of biological weapons — and that could potentially prevent a global pandemic, according to the letter as reported by The Verge.

Tech CEOs Present a United Front to Congress

Among the signatories are Dario Amodei of Anthropic, Sam Altman of OpenAI, and Mustafa Suleyman of Microsoft. It is far from routine for these three companies to speak with one voice — competition between them is fierce on virtually every other front.

The letter targets what its authors describe as an acute gap in biosecurity. The argument is that existing regulations are not designed for a reality in which advanced language models can lower the threshold for who is capable of acquiring knowledge about dangerous pathogens.

Rivals in everything else, but united on one point: AI cannot become a tool for mass death.
AI Giants Ask Congress to Stop the Bioweapons Threat - Bilde 1

What the Letter Actually Demands

Full details of the proposals have not been made public, but according to The Verge, the letter calls for mandatory screening mechanisms and other measures to be imposed on AI companies, preventing their models from providing information that could directly contribute to the design or production of biological weapons.

The backdrop is that large language models — like those developed by all three companies — could in theory be used to accelerate research, including research with harmful potential. The problem is that capabilities are advancing so rapidly that dangerous use cases are often discovered only after a model is already in deployment, according to experts cited in industry analyses.

Experts Disagree on the Solution

Although the letter has attracted widespread attention, there is far from consensus that AI regulation is the right approach. David Baker, director of the Institute for Protein Design at the University of Washington, argues that regulation should primarily target physical barriers — laboratories, equipment, and DNA synthesis technology — rather than the AI tools themselves. Baker, cited in industry analyses, emphasizes that DNA synthesis, which is used in vaccine development, can also deliver components for dangerous pathogens.

Another objection concerns market dynamics: stricter regulations could fall disproportionately hard on startups, while large players with the resources to handle compliance work would strengthen their position. Critics point out that this could paradoxically give the very companies signing the letter a competitive advantage.

Regulation could end up protecting the big players and strangling the small ones — a paradox that no one in the letter addresses openly.

Strategic Motivation or Genuine Responsibility?

Some observers interpret the industry's engagement on biosecurity issues as partly strategic. The thinking is that by pushing for mandatory screening, responsibility is distributed across a broader system — thereby reducing the risk of the entire industry being held collectively accountable if AI is ever linked to a biological incident.

It is worth noting that this is an interpretation offered by critics, not a documented fact. The signatories themselves have not publicly responded to such accusations.

A further complication is that U.S. export control rules, according to industry analyses, may actually impede effective biosecurity development: many of the world's leading biosecurity experts are foreign nationals from countries such as Canada, the United Kingdom, and EU member states, and the licensing processes required to involve them in such testing can be lengthy.

What Happens Next?

The ball is now in Congress's court. Whether lawmakers will actually act — and in what form — remains to be seen. Historically, technology regulation in the United States has moved slowly, but the biosecurity argument has a unique ability to build political support across party lines. The fact that some of the most powerful names in the AI industry are now speaking with one voice may lend the initiative weight — or it may be met with skepticism from lawmakers who question the industry's true motives.